AveXis Inc. (AVXS) Stock Price Down 2.3%
Shares of AveXis Inc. (NASDAQ:AVXS) traded down 2.3% during mid-day trading on Thursday . The stock traded as low as $35.03 and last traded at $36.19, with a volume of 76,929 shares changing hands. The stock had previously closed at $37.06.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, May 26th. Goldman Sachs Group Inc. lifted their target price on shares of AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research report on Friday, May 13th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating and lifted their target price for the company from $39.00 to $42.00 in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of AveXis in a research report on Monday, May 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $43.80.
The firm’s market cap is $867.59 million. The firm has a 50-day moving average price of $41.50 and a 200-day moving average price of $30.16.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.89. Equities research analysts anticipate that AveXis Inc. will post ($4.00) EPS for the current fiscal year.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.